Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Vrijdag vreemd dagje voor dit aandeel. Hoewel ik er geen info over terugvind Et een onderliggende reden. Iemand een idee/feedback?
Het aandeel is omhoog geschoten, > 500%. Waarom? Op het Yahoo forum schreef iemand dit ca. een maand geleden: "We can't change the world, but we can change the subject" ? James Joyce, Ulysses It seems possible that in the near future this could become a fair trading area in $12,5. To assess this area, it is enough to understand that, already in the immediate future, the importance and usefulness of influencing social society in the world, the ADAPTIR platform will appear as a security product to protect and strengthen human immunity. Development of ADAPTIR constructs is a unique approach to the treatment of cancer and hematological disorders, autoimmune and other diseases of the immune system, and what is most important and relevant during today's dramatic events, and possibly new, hypothetical attacks in the ongoing future human world, are infectious diseases.It is important to understand the essence that, without an immune system, a person is susceptible to any virus attack, and in the first place, the Adaptir platform is proven to receive an answer in improving the human immune system to such pandemics. Today, the company is actively seeking opportunities to develop new bispecific #ADAPTIR molecules with pharmaceutical partners. And I would not be surprised if the company has already sent a request to evaluate future partnerships to such companies as Merck, Roche, Pfizer.
Vrijdag al 205 HOGER EN NU 24% HOGER IEMAND EEN IDEE WAAROM DEZE STIJGING VAN DE KOERS??
KOERS APTEVO NU 40% HOGER
Normaal 65.000 stuks p dag nu al ruim 1 miljoen stuks.
Dit is het laatste bericht dat ik vond na een eerste zoektocht. SEATTLE, WA / ACCESSWIRE / April 14, 2020 / Aptevo Therapeutics Inc. (APVO), a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ bispecific technology platform, today announced that it has received notice from The NASDAQ Stock Market LLC (NASDAQ) on April 13, 2020 informing Aptevo that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market. Consequently, Aptevo is now in compliance with all applicable listing standards and its common stock will continue to be listed on The NASDAQ Capital Market. Aptevo was previously notified by NASDAQ on April 18, 2019 that it was not in compliance with the minimum bid price rule because its common stock failed to meet the closing bid price of $1.00 or more for 30 consecutive business days. In order to regain compliance with the Rule, the Company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. This requirement was met on April 9, 2020, the tenth consecutive trading day when the closing bid price of the Company's common stock was over $1.00. About Aptevo Therapeutics Inc. Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The Company's lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603 were developed based on the Company's versatile and robust ADAPTIR™ modular protein technology platform. The ADAPTIR platform is capable of generating highly differentiated bispecific antibodies with unique mechanisms of action for the treatment of different types of cancer. For more information, please visit www.aptevotherapeutics.com Safe Harbor Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, statements regarding potential milestone payments, Aptevo's outlook, financial performance or financial condition, Aptevo's technology and related pipeline, collaboration and partnership opportunities, commercial portfolio, milestones, and any other statements containing the words "believes," "expects," "anticipates," "intends," "plans," "forecasts," "estimates," "will" and similar expressions are forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not undertake to update any forward-looking statement to reflect new information, events or circumstances. There are a number of important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; adverse developments in research and development; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social and political conditions. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, as filed on March 25, 2020 and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo's expectations in any forward-looking statement. CONTACT: Aptevo Therapeutics Stacey Jurchison Senior Director, Investor Relations and Corporate Communications 206-859-6628 JurchisonS@apvo.com SOURCE: Aptevo Therapeutics
De biotech had een ipo rond de 35 dollar en stond 2 jaar terug op ca 80 dollar. Er is dus een opleving van het vertrouwen in deze immuno-oncologie specialist met hun ADAPTIR™ bispecific technology platform. Weet jij meer @ pardon?
Nee ik kan ook niets vinden, maar sta op een leuke winst en verkoop niet je weet niet wat je kunt verwachten kan alle kanten op.
ADAPTIR™ Platform Overview Our development focus centers around our proprietary ADAPTIR platform, a novel approach for the generation of immunotherapeutics. The highly versatile ADAPTIR platform holds great promise for product candidate generation, target validation, and clinical development. We are applying ADAPTIR technology to develop immuno-oncology candidates that focus on redirected T-cell cytotoxicity (RTCC). ADAPTIR technology is modular and can be used to generate immunotherapeutics with unique mechanisms of action including targeted cytokine delivery, targeting two cell surface receptors or neutralization of multiple soluble proteins. ADAPTIR redirected T-cell candidates hold distinct advantages over other immunotherapeutic and bispecific T-cell technologies. In pre-clinical studies, ADAPTIR candidates have been shown to possess superior properties: High potency; ADAPTIR bispecific proteins induce target-dependent cytotoxicity at low concentrations Extended serum half-life that enables less frequent administration Reliable antibody-like manufacturing processes The ADAPTIR platform offers a great opportunity for use in combination with other immunotherapeutics and can also be configured to produce other types of multispecifics.Aptevo Therapeutics and the ADAPTIR™ (Modular Protein Technology) Platform: The Future of Immuno-oncology Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases.
Zij hebben – gezien hun pijplijn - 4 kandidaat-medicijnen/behandelingen die allemaal gebaseerd zijn op de technologie van hun platform Adaptir, RTCC – Redirected T-Cell Cytotoxicity = T-Cell Engager. Slechts 1 daarvan is in fase 1, de overige 3 zijn nog in de pre-klinische fase. Het doet me een beetje denken aan Arrowhead met zijn RNAi platform in 2019. Alle verwachtingswaarde daarvan werd gebaseerd op de nieuwe technologie van het platform. Het idee was dat als de technologie werkt dan kan je daar talloze medicijnen mee ontwikkelen. Toch bleek de praktijk veel weerbarstiger te zijn. Het aandeel is wel gegroeid van 1,5 naar 45! En nu hangt het een beetje. Ik denk dat we maar het beste kunnen gaan naar het yahoo/forum voor de zienswijze van beleggers op het aandeel Aptevo Pharmaceutics. Of @ pardon, beleg jij enkel op de goede gok?
Dit is wat ik bedoel met eerdere toepassingen van het platform / technologie: Multiple Candidates Aptevo Therapeutics is committed to building a robust pipeline of preclinical ADAPTIR™ bispecific candidates with a focus on novel mechanisms of action. By leveraging our proprietary ADAPTIR platform, these new candidates utilize multiple mechanisms of action, including redirected T-cell cytotoxicity (RTCC), T-cell co-stimulators, and targeted cytokine delivery to exploit new biological pathways for the discovery and development of novel cancer and autoimmune therapies.
Partner van Aptevo is het in Zweden gelokaliseerde Alligator Bioscience Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase II studies. ALG.APV.527 kandidaat-medicijn tegen meerdere solide kankers wordt gemeenschappelijk ontwikkeld met Aptevo en zit nog in de klinische fase. Aandeel ALLIGATOR BIOSCIENCE AB CHX:ATORX, SE0000767188
Totaal onbegrijpelijk aandeel: binnen 1 week stijging van 35% en nu binnen een uur na opening beurs al 20% eraf. Er is geen Covid-19 programma; überhaupt geen nieuws, geen bedrijfs- PB, geen concurrent die iets beters heeft etc. etc.
Is er nog iemand die dit aandeel volgt ?
Lego schreef op 11 oktober 2020 19:35 :
Is er nog iemand die dit aandeel volgt ?
Jij?
MisterBlues schreef op 12 oktober 2020 09:46 :
[...]
Jij?
Ik ben het aandeel nog maar recent aan het volgen na een tip hier op het forum. Laatste nieuws van 1 september was dat de ontwikkeling van hun APVO436 middel "op schema" ligt.
Lego schreef op 14 oktober 2020 19:33 :
[...]
Ik ben het aandeel nog maar recent aan het volgen na een tip hier op het forum.
Laatste nieuws van 1 september was dat de ontwikkeling van hun APVO436 middel "op schema" ligt.
Ik hoop dat je het blijft volgen. Ik denk dat hier wel iets meer in het vat zit. Het gaat tenslotte om een uitgebreid bio-technologisch platform.ADAPTIR™ Platform Overview Our development focus centers around our proprietary ADAPTIR platform, a novel approach for the generation of immunotherapeutics. The highly versatile ADAPTIR platform holds great promise for product candidate generation, target validation, and clinical development. We are applying ADAPTIR technology to develop immuno-oncology candidates that focus on redirected T-cell cytotoxicity (RTCC). ADAPTIR technology is modular and can be used to generate immunotherapeutics with unique mechanisms of action including targeted cytokine delivery, targeting two cell surface receptors or neutralization of multiple soluble proteins. ADAPTIR redirected T-cell candidates hold distinct advantages over other immunotherapeutic and bispecific T-cell technologies. In pre-clinical studies, ADAPTIR candidates have been shown to possess superior properties: High potency; ADAPTIR bispecific proteins induce target-dependent cytotoxicity at low concentrations Extended serum half-life that enables less frequent administration Reliable antibody-like manufacturing processes The ADAPTIR platform offers a great opportunity for use in combination with other immunotherapeutics and can also be configured to produce other types of multispecifics. Aptevo Therapeutics and the ADAPTIR™ (Modular Protein Technology) Platform: The Future of Immuno-oncology Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases.
Ik ga het zeker blijven volgen. Voorlopig zonder aandelen te bezitten. Verwacht je op een korte termijn terug een stijging ?
Lego schreef op 16 oktober 2020 19:05 :
Ik ga het zeker blijven volgen. Voorlopig zonder aandelen te bezitten.
Verwacht je op een korte termijn terug een stijging ?
Ik hoopte dat jij dat zou willen uitzoeken? Ik kijk de kat uit de boom!
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
874,02
-0,09%
EUR/USD
1,0707
+0,09%
FTSE 100
8.040,38
-0,06%
Germany40^
18.086,70
-0,01%
Gold spot
2.318,57
+0,11%
NY-Nasdaq Composite
15.712,75
+0,10%
Stijgers
Dalers